Login Register Cart 0
Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Synthesis, Cytotoxicity Evaluation and Molecular Docking of Fluorine Containing Hexahydroquinoline-3-Carbonitrile Derivatives

Author(s): Nishith Teraiya*, Subhas S. Karki and Ashlesha Chauhan

Volume 19, Issue 1, 2022

Published on: 29 December, 2020

Article ID: e140122189603 Pages: 11

DOI: 10.2174/1570163817666201229154848

Price: $65

Abstract

Background: Fluorine containing hexahydroquinoline-3-carbonitrile derivatives were found to have potent cytotoxicity. Furthermore, fluorine can modulate pharmacokinetic and pharmacodynamic profile of drugs. Hence, new derivatives containing fluorine were explored as potential cytotoxic agents.

Objective: Difluoro substituted compounds containing aromatic/heteroaromatic rings were designed, synthesized and screened for in vitro cytotoxicity on cancer cell lines. The active compounds were subjected to docking on Mcl-1 and ADME/T prediction.

Methods: The synthesized compounds were characterized using various spectral techniques like FT-IR, 1H NMR, 13C NMR and Mass spectra. Compounds were screened for cytotoxicity on NCI-60 cell lines at the National Cancer Institute. The active compounds were evaluated additionally by MTT and SRB assay.

Results: Compounds (6l and 6o) showed maximum cytotoxicity with (% GI) of 69 and 63.7 at 10 μM drug concentration, respectively. Compound 6i showed potent cytotoxicity with GI50 of 7.2 μM against Ishikawa cell line. Compound 6o was nearly as active as a reference with IC50 of 9.39 μM and 13.54 μM against HT-29 and HCT-116, respectively, and compound 6l also showed equal potency to that of reference with IC50 of 9.66 μM against Caco-2. Compounds 6i, 6o and 6l showed high docking scores, suggesting their cytotoxicity. Furthermore, ADME/T prediction revealed that all the compounds had drug-likeness properties.

Conclusion: Enhanced lipophilic interaction of compounds due to the presence of fluorine in compounds 6i and 6l was revealed during the docking study. Compound 6i can be explored as a lead molecule against other endometrial cancer in futuristic drug development.

Keywords: Hexahydroquinoline-3-carbonitrile derivatives, cytotoxicity, NCI-60 cell lines, MTT assay, docking, venetoclax, imatinib.

Graphical Abstract

[1]
Biemar F, Foti M. Global progress against cancer-challenges and opportunities. Cancer Biol Med 2013; 10(4): 183-6.
[PMID: 24349827]
[2]
Singh M, Prasad CP, Singh TD, Kumar L. Cancer research in India: Challenges & opportunities. Indian J Med Res 2018; 148(4): 362-5.
[http://dx.doi.org/10.4103/ijmr.IJMR_1711_18] [PMID: 30665997]
[3]
El-Hossary EMM. Synthesis of some heterocyclic compounds bearing sulphonamide moiety and studying their combined anticancer effcets with γ-radiation. PhD Dissertation 2010.
[4]
Maddry JA, Keeton A, Whitt J. 5-Quinolinone and imidazopyridine compounds and use thereof. US Patent 0178106 A1 2011.
[5]
Alqasoumi SI, Al-Taweel AM, Alafeefy AM, Hamed MM, Noaman E, Ghorab MM. Synthesis and biological evaluation of 2-amino-7,7-dimethyl 4-substituted-5-oxo-1-(3,4,5-trimethoxy)-1,4,5,6, 7,8-hexahydro-quinoline-3-carbonitrile derivatives as potential cytotoxic agents. Bioorg Med Chem Lett 2009; 19(24): 6939-42.
[http://dx.doi.org/10.1016/j.bmcl.2009.10.065] [PMID: 19879135]
[6]
Ghorab MM, Ragab FA, Heiba HI, Nissan YM, Ghorab WM. Novel brominated quinoline and pyrimidoquinoline derivatives as potential cytotoxic agents with synergistic effects of γ-radiation. Arch Pharm Res 2012; 35(8): 1335-46.
[http://dx.doi.org/10.1007/s12272-012-0803-6] [PMID: 22941476]
[7]
Ghorab MM, Ragab FA, Heiba HI, Ghorab WM. Design and Synthesis of Some Novel Quinoline Derivatives as Anticancer and Radiosensitizing Agents Targeting VEGFR Tyrosine Kinase. J Heterocycl Chem 2011; 48(6): 1269-79.
[http://dx.doi.org/10.1002/jhet.749]
[8]
El-Ashmawy MB, El-Sherbeny MA, El-Gohary NS. Synthesis and antitumor screening of new series of pyrimido-[4,5-b] quinolines and [1,2,4]triazolo[2′,3′:3,4]pyrimido[6,5-b]quinolines. Med Chem Res 2013; 22(6): 2724-36.
[http://dx.doi.org/10.1007/s00044-012-0272-y]
[9]
Thumar NJ, Patel MP. Synthesis and antimicrobial activity of some new N-substituted quinoline derivatives of 1H-pyrazole. Arch Pharm (Weinheim) 2011; 344(2): 91-101.
[http://dx.doi.org/10.1002/ardp.201000010] [PMID: 21290425]
[10]
Shah NM, Patel MP, Patel RG. New N-arylamino biquinoline derivatives: Microwave-assisted synthesis and their antimicrobial activities. Med Chem Res 2013; 22(1): 312-22.
[http://dx.doi.org/10.1007/s00044-012-0031-0]
[11]
Gouhar RS, Fathy U, El-Zahar MI, Kamel MM, Awad GEA. Synthesis of novel 1,4,5,6,7,8-hexahydroquinolines of potential antimicrobial activity. Acta Pol Pharm -. Acta Pol Pharm 2017; 74(1): 147-59.
[PMID: 29474771]
[12]
Thumar NJ, Patel MP. Synthesis, characterization and biological activity of some new carbostyril bearing 1H-pyrazole moiety. Med Chem Res 2012; 21(8): 1751-61.
[http://dx.doi.org/10.1007/s00044-011-9693-2]
[13]
Chandak N, Bhardwaj JK, Zheleva-Dimitrova D, et al. Effective attenuation of atrazine-induced histopathological changes in testicular tissue by antioxidant N-phenyl-4-aryl-polyhydroquinolines. J Enzyme Inhib Med Chem 2015; 30(5): 722-9.
[http://dx.doi.org/10.3109/14756366.2014.960864] [PMID: 25265324]
[14]
Sapariya NH, Vaghasiya BK, Thummar RP, et al. Synthesis, characterization, in silico molecular docking study and biological evaluation of a 5-(phenylthio) pyrazole based polyhydroquinoline core moiety. New J Chem 2017; 41(19): 10686-94.
[http://dx.doi.org/10.1039/C7NJ01962A]
[15]
Kathrotiya HG, Patel MP. Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents. Eur J Med Chem 2013; 63: 675-84.
[http://dx.doi.org/10.1016/j.ejmech.2013.03.017] [PMID: 23567957]
[16]
Ahmed NS, Badahdah KO, Qassar HM. Novel quinoline bearing sulfonamide derivatives and their cytotoxic activity against MCF7 cell line. Med Chem Res 2017; 26(6): 1201-12.
[http://dx.doi.org/10.1007/s00044-017-1850-9]
[17]
Ghorab MM, Ragab FA, Heiba HI, Arafa RK, El-Hossary EM. Docking study, in vitro anticancer screening and radiosensitizing evaluation of some new fluorine-containing quinoline and pyrimidoquinoline derivatives bearing a sulfonamide moiety. Med Chem Res 2011; 20(3): 388-400.
[http://dx.doi.org/10.1007/s00044-010-9332-3]
[18]
Ghorab MM, Ragab FA, Hamed MM. Design, synthesis and anticancer evaluation of novel tetrahydroquinoline derivatives containing sulfonamide moiety. Eur J Med Chem 2009; 44(10): 4211-7.
[http://dx.doi.org/10.1016/j.ejmech.2009.05.017] [PMID: 19540022]
[19]
Al-Said MS, Ghorab MM, Al-Qasoumi SI, El-Hossary EM, Noaman E. Synthesis and in vitro anticancer screening of some novel 4-[2-amino-3-cyano-4-substituted-5,6,7,8-tetrahydroquinolin-1-(4H)-yl]benzenesulfonamides. Eur J Med Chem 2010; 45(7): 3011-8.
[http://dx.doi.org/10.1016/j.ejmech.2010.03.030] [PMID: 20413187]
[20]
Böhm HJ, Banner D, Bendels S, et al. Fluorine in medicinal chemistry. ChemBioChem 2004; 5(5): 637-43.
[http://dx.doi.org/10.1002/cbic.200301023] [PMID: 15122635]
[21]
Walensky LD, Stewart ML, Cohen N. Small molecules for the modulation of Mcl-1 and method of modulating cell death, cell division. cell differentiation and method of treating disorders US Patent 20150315211A1, 2015.
[22]
Julian L. Structure-based design and synthesis of selective small molecule inhibitors for Mcl-1, an important Cancer Target. MSc Thesis 2015.
[23]
National Cancer Institute. Developmental therapeutic Program [cited: 18 June 2019]; Available from: One dose screen. https://dtp. cancer. gov/discovery _development/nci-60/methodology.htm.
[24]
Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82(13): 1107-12.
[http://dx.doi.org/10.1093/jnci/82.13.1107] [PMID: 2359136]
[25]
Kurokawa M, Wadhwani A, Kai H, et al. Activation of Cellular Immunity in Herpes Simplex Virus Type 1-Infected Mice by the Oral Administration of Aqueous Extract of Moringa oleifera Lam. Leaves. Phytother Res 2016; 30(5): 797-804.
[http://dx.doi.org/10.1002/ptr.5580] [PMID: 26814058]
[26]
Fire E, Gullá SV, Grant RA, Keating AE. Mcl-1-Bim complexes accommodate surprising point mutations via minor structural changes. Protein Sci 2010; 19(3): 507-19.
[http://dx.doi.org/10.1002/pro.329] [PMID: 20066663]
[27]
Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017; 7: 42717.
[http://dx.doi.org/10.1038/srep42717]
[28]
Pajouhesh H, Lenz GR. Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2005; 2(4): 541-53.
[http://dx.doi.org/10.1602/neurorx.2.4.541] [PMID: 16489364]
[29]
National Cancer Institute. Database and Tools DTP bulk data for download. [cited: 10 May 2019]; Available from: https://dtp.cancer. gov/dtpstandard/dwindex/index.jsp.
[30]
Ashkenazi A, Fairbrother WJ, Leverson JD, Souers AJ. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Discov 2017; 16(4): 273-84.
[http://dx.doi.org/10.1038/nrd.2016.253] [PMID: 28209992]

Rights & Permissions Print Cite
Article Metrics
26
1
© 2024 Bentham Science Publishers | Privacy Policy